Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Topical Imiquimod for Bowen's Disease of the Head and Neck
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Prevention, Treatment
Enrolling by invitation
18 and over
Other
C.2005.087
NCT00384124
Last Modified:
6/25/2007
 
First Published:
7/26/2003
2.
Phase III Randomized Study of Topical Imiquimod Versus Excisional Surgery in Patients With Nodular or Superficial Basal Cell Skin Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Any age
Other
CRUK-LON-SINS-C7484/A2869
EU-20205, NCT00066872
Last Modified:
4/30/2004
 
First Published:
3/1/2002
3.
Phase II Randomized Chemoprevention Study of Topical Imiquimod Preceding Local Ablative or Excisional Therapy in Patients With Recurrent or High-Grade Cervical Intraepithelial Neoplasia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Prevention
Closed
18 and over
NCI
NCCTG-989251
NCI-P02-0208, NCT00031759
Last Modified:
9/9/2005
 
First Published:
2/20/2004
4.
Phase I Randomized Study of Imiquimod 5% Cream in Patients With Basal Cell Skin Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
NCI-02-CC-0289
3M-1454-IMIQ, NCT00079300
Last Modified:
7/10/2006
 
First Published:
6/25/2005
5.
Phase I Randomized Study of Adjuvant Transdermal Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides, Tetanus Toxoid Helper Peptide, and Sargramostim (GM-CSF) in Combination With Either Montanide ISA-51 or Dimethyl Sulfoxide With or Without Imiquimod in Patients With Resected Stage II-IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
12 and over
NCI
UVACC-MEL-45
UVACC-HIC-11490, UVACC-34204, NCT00118313
6.
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
Other
NYU 04-53, LUD2004-006
NCT00142454
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute